2015 Medicines in Development for Neurological Disorders A Report on Disorders of the Brain, Spinal Cord and Nerves Alzheimer's Disease Product Name Sponsor Indication Development Phase AC-1204 Accera mild to moderate Alzheimer's disease Phase II/III (caprylic triglyceride) Broomfield, CO www.accerapharma.com ACI-35 AC Immune Alzheimer's disease Phase I (active anti-Tau vaccine) Lausanne, Switzerland www.acimmune.com Janssen Research & Development www.janssenrnd.com Raritan, NJ AD-4833/TOMM40 Takeda Pharmaceutical delay onset of mild cognitive Phase III (insulin sensitizer) Deerfield, IL impairment due to Alzheimer's www.takeda.com Zinfandel Pharmaceuticals disease Chapel Hill, NC aducanumab (BIIB037) Biogen Alzheimer's disease Phase I (amyloid beta-protein inhibitor) Cambridge, MA www.biogen.com ALZ-801 Alzheon Alzheimer's disease Phase I (amyloid beta-protein inhibitor) Framingham, MA www.alzheon.com ANAVEX Plus Anavex Life Sciences Alzheimer's disease Phase II (ANAVEX 2-73/donepezil) New York, NY www.anavex.com ASP3662 Astellas Pharma US Alzheimer's disease Phase I Northbrook, IL www.astellas.us Alzheimer's Disease Product Name Sponsor Indication Development Phase AVN-101 AllaChem Alzheimer's disease Phase II (serotonin 6 receptor antagonist) Hallandale, FL www.allachem.com Avineuro Pharmaceuticals San Diego, CA AVN-322 AllaChem Alzheimer's disease Phase II (serotonin 6 receptor antagonist) Hallandale, FL www.allachem.com Avineuro Pharmaceuticals San Diego, CA AVP-786 Avanir Pharmaceuticals agitation in Alzheimer's disease Phase I (dextromethorphan analogue/quinidine) Aliso Viejo, CA www.avanir.com Concert Pharmaceuticals www.concertpharma.com Lexington, MA AVP-923 Avanir Pharmaceuticals agitation in Alzheimer's disease Phase II (dextromethorphan/quinidine San Diego, CA (see also headache, Parkinson's) www.avanir.com fixed-dose combination) AZD3293 AstraZeneca Alzheimer's disease Phase II (beta-secretase inhibitor) Wilmington, DE www.astrazeneca.com Eli Lilly www.lilly.com Indianapolis, IN azeliragon (TTP488) vTv Therapeutics Alzheimer's disease (Fast Track) Phase III (RAGE antagonist) High Point, NC www.vtvtherapeutics.com Alzheimer's Disease Product Name Sponsor Indication Development Phase BACE inhibitor CoMentis Alzheimer's disease Phase I completed South San Francisco, CA www.comentis.com BACE inhibitor Eli Lilly Alzheimer's disease Phase I Indianapolis, IN www.lilly.com BACE inhibitor Janssen Pharmaceuticals early-stage Alzheimer's disease Phase II Titusville, NJ www.janssenpharmaceuticalsinc.com Shionogi www.shionogi.co.jp Osaka, Japan BAN2401 Biogen Alzheimer's disease Phase II (amyloid beta-protein inhibitor) Cambridge, MA www.biogen.com Eisai www.eisai.com Woodcliff Lake, NJ BI 409306 Boehringer Ingelheim Alzheimer's disease Phase II (phosphodiesterase 9A inhibitor) Pharmaceuticals www.boehringer-ingelheim.com Ridgefield, CT bisnorcymserine QR Pharma advanced Alzheimer's disease Phase I (BNC) Berwyn, PA www.qrpharma.com bryostatin-1 Neurotrope BioScience Alzheimer's disease Phase II Newark, NJ www.neurotropebioscience.com Alzheimer's Disease Product Name Sponsor Indication Development Phase CAD106 GlaxoSmithKline Alzheimer's disease Phase II completed (beta-amyloid protein inhibitor) Research Triangle Park, NC www.gsk.com CPC-201 Chase Pharmaceuticals Alzheimer's disease Phase II Washington, DC www.chasepharmaceuticals.com crenezumab Genentech mild to moderate Alzheimer's disease Phase II (beta-amyloid protein inhibitor) South San Francisco, CA www.gene.com E2609 Biogen Alzheimer's disease Phase II (BACE1 protein inhibitor) Cambridge, MA www.biogen.com Eisai www.eisai.com Woodcliff Lake, NJ ELND005 Transition Therapeutics agitation/aggression in Alzheimer's Phase II (amyloid-beta protein inhibitor) Toronto, Canada disease (Fast Track) www.transitiontherapeutics.com encenicline Forum Pharmaceuticals Alzheimer's disease Phase III (alpha-7 potentiator) Watertown, MA www.forumpharma.com gantenerumab Genentech early-stage Alzheimer's disease Phase III (amyloid-beta protein inhibitor) South San Francisco, CA www.gene.com GC021109 GliaCure mild to moderate Alzheimer's disease Phase I (purinoceptor P2Y6 agonist) Boston, MA (Fast Track) www.gliacure.com Alzheimer's Disease Product Name Sponsor Indication Development Phase idalopirdine Lundbeck Alzheimer's disease Phase III (serotonin 6 receptor antagonist) Deerfield, IL www.lundbeck.com Otsuka Pharmaceutical www.otsuka.co.jp Tokyo, Japan immune globulin Grifols USA Alzheimer's disease Phase III Los Angeles, CA www.grifols.com JNJ-54861911 Janssen Research & Development Alzheimer's disease Phase II Raritan, NJ www.janssenrnd.com LMTX TauRx Pharmaceuticals Alzheimer's disease Phase III (tau protein aggregation/ Singapore www.taurx.com TDP-43 aggregation inhibitor) Lu-AF20513 Lundbeck Alzheimer's disease Phase I (amyloid beta-protein inhibitor) Deerfield, IL www.lundbeck.com Otsuka Pharmaceutical www.otsuka.co.jp Tokyo, Japan LY3002813 Eli Lilly Alzheimer's disease Phase I (N3pG-Aß mAb) Indianapolis, IN www.lilly.com MEDI1814 MedImmune Alzheimer's disease Phase I (anti-amyloid beta mAb) Gaithersburg, MD www.medimmune.com mGlu2 agonist Eli Lilly Alzheimer's disease psychosis Phase I Indianapolis, IN www.lilly.com Alzheimer's Disease Product Name Sponsor Indication Development Phase MK-7622 Merck Alzheimer's disease Phase II (quinazolinone) Whitehouse Station, NJ (adjunct therapy) www.merck.com MK-8931 Merck Alzheimer's disease Phase III (BACE1 protein inhibitor) Whitehouse Station, NJ www.merck.com MSDC-0160 Metabolic Solutions Development Alzheimer's disease Phase II completed (mitochondrial protein stimulant) Kalamazoo, MI www.msdrx.com NIC-515 Humanetics Alzheimer's disease Phase II (amyloid precursor protein secretase Minneapolis, MN www.humaneticscorp.com inhibitor) PF-05212377 (SAM-760) Pfizer Alzheimer's disease Phase II (5HT6 antagonist) New York, NY www.pfizer.com PF-06648671 Pfizer Alzheimer's disease Phase I New York, NY www.pfizer.com Posiphen® QR Pharma Alzheimer's disease Phase II R-phenserine Berwyn, PA (see also Parkinson's) www.qrpharma.com PTI-80 ProteoTech Alzheimer's disease Phase I (amyloid beta/tau protein inhibitor) Kirkland, WA www.proteotech.com Alzheimer's Disease Product Name Sponsor Indication Development Phase RG1577 Roche Alzheimer's disease Phase II (MAO-B inhibitor) New York, NY www.roche.com RG7345 Roche Alzheimer's disease Phase I (anti-Tau mAb) New York, NY www.roche.com rilapladib GlaxoSmithKline Alzheimer's disease Phase II (Lp-PLA2 inhibitor) Research Triangle Park, NC www.gsk.com RVT-101 Axovant Sciences mild to moderate Alzheimer's disease Phase II completed (5-HT6 receptor antagonist) New York, NY www.axovant.com RVX208 Resverlogix Alzheimer's disease Phase I completed (BET protein inhibitor) Calgary, Canada www.resverlogix.com SAR228810 Sanofi US Alzheimer's disease Phase I (anti-protofibrillar AB mAb) Bridgewater, NJ www.sanofi.com sGC 1061 sGC Pharma Alzheimer's disease Phase I (nomethiazole) Vancouver, Canada sgcpharma.com solanezumab Eli Lilly Alzheimer's disease Phase III (amyloid beta protein inhibitor) Indianapolis, IN www.lilly.com SUVN-502 Suven Life Sciences Alzheimer's disease Phase I (serotonin 6 receptor antagonist) Hyderabad, India www.suven.com Alzheimer's Disease Product Name Sponsor Indication Development Phase SUVN-G3031 Suven Life Sciences cognitive dysfunction in Phase I (histamine H3 receptor antagonist) Hyderabad, India Alzheimer's disease www.suven.com T-817MA Toyama Chemical Alzheimer's disease Phase II (amyloid beta-protein inhibitor) Tokyo, Japan www.toyama-chemical.co.jp T3D-959 T3D Therapeutics Alzheimer's disease Phase I (PPAR-delta/gamma agonist) Research Triangle Park, NC www.t3dtherapeutics.com TPI 287 Cortice Biosciences mild to moderate Alzheimer's disease Phase I (abeotaxane) New York, NY (see also brain tumors, other) www.corticebio.com UB-311 United Biomedical Alzheimer's disease Phase I (amyloid beta-protein inhibitor) Hauppauge, NY www.unitedbiomedical.com VX-745 EIP Pharma Alzheimer's disease Phase II (p38 mitogen-activated protein Cambridge, MA www.eippharma.com kinase inhibitor) Amyotrophic Lateral Sclerosis Product Name Sponsor Indication Development Phase arimoclomal ALS Foundation hereditary or familial Phase II/III Orphan Drug Washington, DC amyotrophic lateral sclerosis (ALS) www.orphazyme.com Orphazyme (Fast Track) Copenhagen, Denmark University of Miami Miami, FL CC100 Chemigen ALS Phase I completed Indianapolis, IN dexpramipexole Knopp Biosciences ALS (Fast Track) Phase II Orphan Drug Pittsburgh, PA www.knoppbio.com GM6 Genervon Biopharmaceuticals ALS (Fast Track) Phase II (peptide therapeutic) Pasadena, CA (see also Parkinson's, stroke) www.genervon.com Orphan Drug H.P. Acthar® Gel Mallinckrodt Pharmaceuticals ALS Phase II repository corticotropin injection St. Louis, MO www.mallinckrodt.com MN-166 MediciNova ALS Phase II (ibudilast) La Jolla, CA (see also multiple sclerosis) www.medicinova.com neurotrophic factor-producing adult BrainStorm Cell Therapeutics ALS (Fast Track) Phase II stem cell therapy (MSC-NTF cells) Hackensack, NJ www.brainstorm-cell.com Orphan Drug Amyotrophic Lateral Sclerosis Product Name Sponsor Indication Development Phase NP001 Neuraltus Pharmaceuticals ALS Phase II (macrophage modulator) Palo Alto, CA www.neuraltus.com NSI-566 Neuralstem ALS Phase II (spinal cord-derived neural Germantown, MD (see also spinal cord injury, stroke) www.neuralstem.com stem cell therapy) Orphan Drug ozanezumab GlaxoSmithKline ALS Phase II (NOGO-A inhibitor) Research Triangle